Hoth Therapeutics (NASDAQ: HOTH) has announced the filing of two U.S. provisional patent applications to expand its IP portfolio and establish a new oncology-focused dermatology platform targeting treatment-induced skin toxicity from modern cancer therapies.
According to Hoth, these patent filings secure priority IP around the use of HT-001, a receptor antagonist with a well-established pharmacologic profile, to treat dermatologic toxicities across multiple oncology treatment modalities, including radiation therapy and next-generation targeted agents. The company believes this approach may represent a novel and potentially first-in-class strategy within the rapidly expanding oncology supportive-care and oncodermatology markets.
In a statement, Robb Knie, founder, president, and CEO of Hoth, commented, “These filings represent a meaningful expansion of our intellectual property estate into an increasingly important area of oncology care. As cancer therapies advance, the ability to manage treatment-related toxicities is becoming essential. We believe this emerging platform highlights our strategy of identifying differentiated, mechanism-driven opportunities that can address significant unmet needs while creating long-term shareholder value.”
